|
Gene: NR2F2 |
Gene summary for NR2F2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NR2F2 | Gene ID | 7026 |
Gene name | nuclear receptor subfamily 2 group F member 2 | |
Gene Alias | ARP-1 | |
Cytomap | 15q26.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P24468 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7026 | NR2F2 | GSM4909282 | Human | Breast | IDC | 1.05e-09 | 3.49e-01 | -0.0288 |
7026 | NR2F2 | GSM4909286 | Human | Breast | IDC | 2.83e-04 | 1.74e-01 | 0.1081 |
7026 | NR2F2 | GSM4909291 | Human | Breast | IDC | 3.11e-11 | 5.62e-01 | 0.1753 |
7026 | NR2F2 | GSM4909293 | Human | Breast | IDC | 1.73e-33 | 6.41e-01 | 0.1581 |
7026 | NR2F2 | GSM4909308 | Human | Breast | IDC | 8.63e-06 | 3.36e-01 | 0.158 |
7026 | NR2F2 | GSM4909311 | Human | Breast | IDC | 3.94e-03 | -3.93e-02 | 0.1534 |
7026 | NR2F2 | GSM4909317 | Human | Breast | IDC | 1.88e-03 | 3.23e-01 | 0.1355 |
7026 | NR2F2 | GSM4909319 | Human | Breast | IDC | 5.01e-06 | -1.55e-01 | 0.1563 |
7026 | NR2F2 | brca10 | Human | Breast | Precancer | 1.37e-02 | -9.38e-02 | -0.0029 |
7026 | NR2F2 | M2 | Human | Breast | IDC | 3.09e-02 | 1.40e-01 | 0.21 |
7026 | NR2F2 | M5 | Human | Breast | IDC | 3.92e-11 | 8.81e-01 | 0.1598 |
7026 | NR2F2 | NCCBC14 | Human | Breast | DCIS | 1.11e-04 | 2.92e-01 | 0.2021 |
7026 | NR2F2 | NCCBC5 | Human | Breast | DCIS | 2.29e-05 | 4.96e-02 | 0.2046 |
7026 | NR2F2 | P1 | Human | Breast | IDC | 2.59e-02 | -5.21e-02 | 0.1527 |
7026 | NR2F2 | P3 | Human | Breast | IDC | 5.07e-03 | 5.13e-01 | 0.1542 |
7026 | NR2F2 | DCIS2 | Human | Breast | DCIS | 3.44e-09 | 6.72e-02 | 0.0085 |
7026 | NR2F2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.15e-16 | 4.66e-01 | -0.1954 |
7026 | NR2F2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.14e-05 | 3.00e-01 | -0.1464 |
7026 | NR2F2 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.60e-02 | 2.29e-01 | -0.1001 |
7026 | NR2F2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.06e-03 | 2.37e-01 | -0.059 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00303365 | Prostate | BPH | negative regulation of cell migration | 86/3107 | 344/18723 | 3.93e-05 | 4.25e-04 | 86 |
GO:00075656 | Prostate | BPH | female pregnancy | 54/3107 | 193/18723 | 4.64e-05 | 4.87e-04 | 54 |
GO:00607063 | Prostate | BPH | cell differentiation involved in embryonic placenta development | 13/3107 | 25/18723 | 5.04e-05 | 5.21e-04 | 13 |
GO:0050680 | Prostate | BPH | negative regulation of epithelial cell proliferation | 47/3107 | 164/18723 | 7.39e-05 | 7.22e-04 | 47 |
GO:00447066 | Prostate | BPH | multi-multicellular organism process | 59/3107 | 220/18723 | 8.01e-05 | 7.66e-04 | 59 |
GO:00105946 | Prostate | BPH | regulation of endothelial cell migration | 61/3107 | 232/18723 | 1.13e-04 | 1.03e-03 | 61 |
GO:00084063 | Prostate | BPH | gonad development | 58/3107 | 221/18723 | 1.73e-04 | 1.48e-03 | 58 |
GO:00147066 | Prostate | BPH | striated muscle tissue development | 91/3107 | 384/18723 | 1.90e-04 | 1.57e-03 | 91 |
GO:00457863 | Prostate | BPH | negative regulation of cell cycle | 91/3107 | 385/18723 | 2.10e-04 | 1.71e-03 | 91 |
GO:00451373 | Prostate | BPH | development of primary sexual characteristics | 58/3107 | 227/18723 | 3.67e-04 | 2.71e-03 | 58 |
GO:00075483 | Prostate | BPH | sex differentiation | 68/3107 | 276/18723 | 3.75e-04 | 2.76e-03 | 68 |
GO:1904030 | Prostate | BPH | negative regulation of cyclin-dependent protein kinase activity | 14/3107 | 33/18723 | 4.08e-04 | 2.97e-03 | 14 |
GO:00018935 | Prostate | BPH | maternal placenta development | 14/3107 | 35/18723 | 8.33e-04 | 5.41e-03 | 14 |
GO:0045736 | Prostate | BPH | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 13/3107 | 32/18723 | 1.07e-03 | 6.67e-03 | 13 |
GO:00323558 | Prostate | BPH | response to estradiol | 38/3107 | 141/18723 | 1.25e-03 | 7.57e-03 | 38 |
GO:00719012 | Prostate | BPH | negative regulation of protein serine/threonine kinase activity | 33/3107 | 120/18723 | 1.76e-03 | 1.01e-02 | 33 |
GO:00601355 | Prostate | BPH | maternal process involved in female pregnancy | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:00606742 | Prostate | BPH | placenta blood vessel development | 11/3107 | 30/18723 | 6.48e-03 | 2.92e-02 | 11 |
GO:00605383 | Prostate | BPH | skeletal muscle organ development | 40/3107 | 166/18723 | 8.09e-03 | 3.52e-02 | 40 |
GO:00075175 | Prostate | BPH | muscle organ development | 71/3107 | 327/18723 | 9.00e-03 | 3.84e-02 | 71 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NR2F2 | SNV | Missense_Mutation | novel | c.1064A>C | p.Asn355Thr | p.N355T | P24468 | protein_coding | tolerated(0.42) | possibly_damaging(0.543) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
NR2F2 | SNV | Missense_Mutation | c.1094N>C | p.Leu365Pro | p.L365P | P24468 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
NR2F2 | SNV | Missense_Mutation | c.653N>A | p.Arg218Lys | p.R218K | P24468 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NR2F2 | SNV | Missense_Mutation | c.1102C>A | p.Pro368Thr | p.P368T | P24468 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
NR2F2 | SNV | Missense_Mutation | novel | c.814N>A | p.Ala272Thr | p.A272T | P24468 | protein_coding | deleterious(0.01) | benign(0.272) | TCGA-GH-A9DA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NR2F2 | SNV | Missense_Mutation | novel | c.823C>A | p.Leu275Met | p.L275M | P24468 | protein_coding | tolerated(0.12) | probably_damaging(0.97) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
NR2F2 | SNV | Missense_Mutation | c.911N>T | p.Ala304Val | p.A304V | P24468 | protein_coding | tolerated(0.08) | benign(0.022) | TCGA-AA-3678-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | CR | |
NR2F2 | SNV | Missense_Mutation | c.1112N>A | p.Arg371His | p.R371H | P24468 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
NR2F2 | SNV | Missense_Mutation | novel | c.517N>T | p.Asn173Tyr | p.N173Y | P24468 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-AA-3855-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NR2F2 | SNV | Missense_Mutation | c.899N>G | p.Glu300Gly | p.E300G | P24468 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7026 | NR2F2 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | CYCLOHEXIMIDE | CYCLOHEXIMIDE | ||
7026 | NR2F2 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | GNF-PF-1678 | CHEMBL580340 | ||
7026 | NR2F2 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | TCMDC-125620 | CHEMBL530291 | ||
7026 | NR2F2 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | RESACTIN A | RESACTIN A | ||
7026 | NR2F2 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | PYRIDABEN | PYRIDABEN | ||
7026 | NR2F2 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | GNF-PF-4659 | CHEMBL584442 |
Page: 1 |